CD36 and Hepatic steatosis: Hence, ezetimibe may ameliorate hepatic insulin resistance in addition to dyslipidemia and hepatic steatosis, partly via a pathway involving CD36 in high-fat diet-induced B6 mouse models of NAFLD.